01—Abstract
Summary
Summary of the 8-K filed August 15, 2024. Cited figures are marked; the original filing is the authoritative source.
Centene Corporation (NYSE: CNC) filed an 8-K on August 15, 2024 to disclose the election of Thomas R.
Greco to its Board of Directors, effective August 9, 2024. The board expanded from 10 to 11 members to create the seat, and Greco's term runs through the 2025 annual meeting of stockholders. The filing is governance-focused and contains no financial results, guidance, or operating metrics, so it carries no direct earnings or valuation signal.
Greco brings substantial consumer-sector leadership: he served as President and CEO of Advance Auto Parts from 2016 to 2023, previously led Frito-Lay North America at PepsiCo, and spent roughly three decades at PepsiCo overall. He also sits on the boards of Tapestry, Inc. and the Sabra Dipping Company joint venture. Centene's CEO Sarah M.
London framed the addition as adding consumer-marketing expertise to help transform the health of 28.5 million Americans. He will receive standard non-employee director compensation, and the company disclosed no family relationships or related-party transactions involving him.
For investors, this is a routine board refresh rather than a material event. The appointment is notable mainly as a sign of board composition strategy, bringing consumer-focused operating experience to a managed care company, and it does not change the company's near-term financial outlook.
02—Key points
Key Highlights
- Thomas R. Greco was elected to Centene's Board effective August 9, 2024, expanding the board from 10 to 11 members.
- Greco's term expires at the 2025 annual meeting of stockholders.
- Greco was President and CEO of Advance Auto Parts (2016-2023) and previously CEO of PepsiCo's Frito-Lay North America (2011-2016).
- Greco will receive Centene's standard non-employee director compensation, as described in the March 28, 2024 proxy statement.
- No family relationships, related-party transactions under Item 404(a), or special election arrangements were disclosed.
- The 8-K is governance-related and contains no financial results, earnings guidance, or operational metrics.
- Centene's CEO cited Greco's consumer-marketing expertise as relevant to serving 28.5 million Americans.
03—Questions
Frequently Asked Questions
Does this board appointment change Centene's financial outlook?
No. The filing is a board governance update and contains no financial results, guidance, or forecasts. Board additions of this kind typically have little direct impact on financial performance.
Why is a consumer-goods executive joining a healthcare company's board?
Centene's CEO said Greco's consumer-marketing and leadership experience will add value as the company works to improve member health. Companies often add directors with complementary skills, such as brand, marketing, or consumer engagement expertise, even outside their core industry.
How long will Greco serve on the board?
His term runs through Centene's 2025 annual meeting of stockholders, after which he would need to be re-elected by shareholders to continue serving.
Is Greco compensated differently from other directors?
No. He will participate in Centene's standard non-employee director compensation program, as described in the company's March 28, 2024 proxy statement.
Are there any conflicts of interest disclosed?
The filing states there are no family relationships between Greco and any Centene director or executive officer, and no related-party transactions of the kind requiring disclosure under Item 404(a) of Regulation S-K in which he participated.
04—Continue